Drug Profile
Iron sucrose/tin protoporphyrin - Renibus Therapeutics
Alternative Names: FeS/SnPP; RBT-1; Stannous protoporphyrin/iron sucrose; Tin-protoporphyrin/iron-sucroseLatest Information Update: 27 Oct 2023
Price :
$50
*
At a glance
- Originator Renibus Therapeutics
- Class Antianaemics; Heavy metals; Urologics
- Mechanism of Action Decyclizing heme oxygenase inhibitors; Interleukin 10 stimulants; Iron replacements; NF E2 related factor 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Acute kidney injury
- No development reported Renal failure